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Abstract Antibiotics have been a panacea in animal
husbandry as well as in human therapy for decades. The
huge amount of antibiotics used to induce the growth and
protect the health of farm animals has lead to the evolution
of bacteria that are resistant to the drug’s effects. Today,
many researchers are working with bacteriophages (pha-
ges) as an alternative to antibiotics in the control of
pathogens for human therapy as well as prevention, bio-
control, and therapy in animal agriculture. Phage therapy
and biocontrol have yet to fulfill their promise or potential,
largely due to several key obstacles to their performance.
Several suggestions are shared in order to point a direction
for overcoming common obstacles in applied phage tech-
nology. The key to successful use of phages in modern
scientific, farm, food processing and clinical applications is
to understand the common obstacles as well as best prac-
tices and to develop answers that work in harmony with
nature.
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Abbreviations
CDC Centres for Disease Control and Prevention
EFSA European Food Safety Authority
FAO Food and Agriculture Organization of the
United Nations
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FSA Food Standards Agency
GPAs Growth promoting antibiotics
GRAS Generally recognized as safe
LPS Lipopolysaccharide
MR Multiplicity reactivation
OIE World Organization for Animal Health
R&D Research and Development
US-FSIS US-Food Safety and Inspection Service
WHO World Health Organization
Introduction
Throughout much of the twentieth century, antibiotics have
been a primary defense against bacterial disease. Unfor-
tunately, inappropriate and excessive use of antibiotics in
animal husbandry is threatening their efficacy.
This review of current issues and causality concerning
antibiotic resistance, points out some opportunities and
uses for bacteriophage treatment and biocontrol in farm-
related applications where the majority of antibiotics at
subtherapeutic levels have been used as well as in clinical
settings and summarizes some of the stumbling blocks that
have emerged during past experimentation. The published
work to date on bacteriophage therapy is supplemented
with some suggestions for future direction in the field. By
following best practices for the use of bacteriophage in
farming and processing applications as well as in a
potential human therapy and rising from challenges already
and yet to be encountered, modern science can avoid a
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repeat of the resistance phenomenon encountered with
antibiotics. A recap of the challenges for using bacterio-
phages in these varied but related settings along with some
potential solutions or best practices is provided to aid
future research.
Agricultural antibiotics
Antibiotics are not only used to treat human illness but
have also been used in livestock and poultry for more than
half a century to control and treat diseases and in sub-
therapeutic doses in animal feed, to promote growth and
improve production of animal products (Stokstad and Jukes
1949; Page and Gautier 2012). This has resulted in the
development of antibiotic-resistant bacteria (Lu 2004); the
consequences affect everybody in the world and access to
effective treatment for bacterial infections is urgently
needed (Laxminarayan et al. 2013). Findings from recent
studies using whole genome sequencing have now con-
firmed animal-to-human transfers of resistance genes
(Harrison et al. 2013).
In agricultural industries, anti-microbial treatment in
terrestrial animals reared for food production is for enteric
and respiratory disorders in young animals and mastitis in
dairy cows (Page and Gautier 2012). Anti-infective drugs
for livestock now represent one of the largest markets in
the world (Page and Gautier 2012). In the U.S. for instance,
around 8 billion animals, (7.5 billion chickens, 300 million
turkeys, and 100 million cattle) are treated by as many as
10 different antibiotics annually or during their lives
(Martin 2004; Page and Gautier 2012). Antibiotics have
also been used for prevention via feed or water to animals
(Page and Gautier 2012; Laxminarayan et al. 2013). Pre-
ventive use can be anything from targeted interventions for
controlling the spread of a diagnosed disease in a defined
group of animals, to routine treatment of all animals during
specific periods of stress such as weaning, after transpor-
tation, when combining new animals with a herd or mixing
animals from different sources (Laxminarayan et al. 2013).
With some exceptions, the antimicrobial classes used in
agricultural industries are the same as in human medicine.
However, some newer types of antimicrobials, such as
carbapenems, oxazolidinones, and glycylcyclines are not
used for animals reared for food (Laxminarayan et al.
2013).
Today, subtherapeutic antibiotics are routinely fed to
livestock, poultry and fish on industrial farms to promote
faster growth and to compensate for the unsanitary condi-
tions in which they are raised (Emanuele 2010). Tetracy-
cline, penicillin, erythromycin, and other antimicrobials
that are important in human clinic are used extensively, in
the absence of disease, for subtherapeutic purposes in
today’s livestock production (Mellon et al. 2001; Page and
Gautier 2012). In the US, overall use of antimicrobials for
subtherapeutic purposes in animals rose by about 50 %
between 1985 and 2001 (Gerber et al. 2007), and approx-
imately 80 % of all antibiotics used in the U.S. are fed to
farm animals (US Congress 2011). This was primarily
driven by increased use in the poultry industry, where
subtherapeutic antibiotic use increased from 2 million to
10.5 million pounds (907,185 kg to 4,762,720 kg) between
the 1980s and 2001 which amounted to a dramatic 307 %
increase on a per-bird basis (Mellon et al. 2001). In addi-
tion, where authorised, antibiotics used for growth pro-
motion can generally be purchased over the counter
without veterinary involvement (Khachatourians 1998;
Manna et al. 2006; Laxminarayan et al. 2013). These
practices have been decreasing the effectiveness of anti-
biotics in treating common infections, which has quickened
in recent years, and the arrival of untreatable strains of
carbapenem-resistant Enterobacteriaceae, indicates that
the world is marching at the dawn of a post-antibiotic era
(CDC 2013).
Additionally, it is estimated that approximately 75 % of
all antibiotics given to animals are not fully digested and
eventually pass through the body and enter the environ-
ment (Chee-Sanford et al. 2009), where they can encounter
new bacteria and create additional resistant strains (Horri-
gan et al. 2002). With huge quantities of manure routinely
sprayed onto fields surrounding confined animal feeding
operations, antibiotic resistant bacteria can leech into sur-
face and ground water, contaminating drinking wells and
endangering the health of people living nearby (Clemans
et al. 2011). Bacteria can also be spread by animals, birds
and insects that come in contact with animal waste (Gra-
ham et al. 2009; Page and Gautier 2012). A considerable
amount of pressure is being exerted on the natural micro-
bial environment, including beneficial bacteria, human and
animal nutrition and immunity, by the antibiotics provided
to humans, animals and plants, as well as the spraying of
antibiotics on fruit trees, resulting in dangerous superbugs
(Phillips et al. 2004; Yan and Polk 2004; O’Hara and
Shanahan 2006; Buffie et al. 2011).
Economic impacts of subtherapeutic use of antibiotics
In 1998, the National Academy of Sciences calculated that
increased health care costs associated with antibiotic-
resistant bacteria exceed $4 billion each year in the U.S.
alone, a figure that reflects the price of pharmaceuticals and
longer hospital stays, but does not account for lost work-
days, lost productivity or human suffering (Knobler et al.
2003; Westwater et al. 2003; U.S. Congress 2011). In 2009,
Cook County Hospital and the Alliance for Prudent Use of
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Antibiotics estimated that the total health care cost of
antibiotic resistant infections in the US was between $16.6
and $26 billion annually (U.S. Congress 2011). The WHO,
the American Medical Association and the American
Public Health Association have urged a ban on GPAs,
arguing that their use leads to increased antibiotic-resistant
infections in humans (Graham et al. 2007). Along with
expected decreases in health care costs that would stem
from reducing the number of drug resistant infections, there
is evidence to show that eliminating GPAs would be
profitable for both farmers and the public as a whole (U.S.
Congress 2011). However, according to a study of Graham
et al. (2007), the increased selling price of chickens fed
GPAs did not offset the increased cost of the feed, resulting
in a higher overall cost to the farmer. The study found that
the use of GPAs resulted in an average loss in value per
chicken of $0.0093, or about 0.45 % of total cost (Graham
et al. 2007).
Today, many animal farmers do not use GPA’s, in large
part because they don’t have to compensate for unhealthy
conditions associated with confined animal feeding opera-
tions (Graham et al. 2007). On these types of farms such as
organic poultry farms, Enterococcus faecalis and E. fae-
cium resistance to antibiotics has been found to be signif-
icantly lower than on conventional poultry farms (Sapkota
et al. 2011). These organic animals are raised in clean
environments with adequate space to reduce animal-stress
and the likelihood of infections (Graham et al. 2007).
These types of farms may use antibiotics to treat acute
infections in sick animals (Graham et al. 2007). These
results do suggest that completely removing antibiotics
from animal agriculture could effectively reduce resis-
tance. In contrast, commercial interests have argued that
their removal will have a significant impact on the cost of
animal production and is unlikely to affect the risk to
humans from antibiotic-resistant infections (Casewell et al.
2003). The economic impact of judicious use or a ban of
antibiotics use in animals is difficult to measure, partly
because exact figures for employees and profits in feed
additives are not available and partly due to this conflicting
evidence.
Government intervention
The precise effect of agricultural antibiotic use on resis-
tance levels in the general population is not known, but the
evidence points to a link (Ganguly et al. 2011). In 2003, an
expert committee convened by the WHO, the United
Nations Food and Agriculture Organization and the World
Organization for Animal Health concluded there is clear
evidence of adverse human health consequences due to
resistant organisms resulting from non-human usage of
antimicrobials (Ganguly et al. 2011). These consequences
include infections that would not have otherwise occurred,
increased frequency of treatment failures (in some cases
death), and increased severity of infections (FAO/OIE/
WHO 2003). Today, governments around the world are
taking action to address this issue. The Director-General of
the WHO, said in 2011 that ‘The world is on the brink of
losing these miracle cures (antibiotics). In the absence of
urgent corrective and protective actions, the world is
heading towards a post-antibiotic era, in which many
common infections will no longer have a cure’ (Liljeqvist
et al. 2012).
In Europe, restricted authorisation of antimicrobial types
began several decades ago and in 2006 all growth pro-
moting use was abandoned (Laxminarayan et al. 2013). In
the US, the FDA has released draft guidelines on judicious
use of antimicrobials in the rearing of animals for food
production. These recommendations aim to reduce the
overall use of medically important anti microbials and
include veterinary oversight and consultation. If this
guidance is adhered to, a gradual phasing out of growth
promoting use is to be expected (Laxminarayan et al.
2013).
The need for an alternative to antibiotics
Each year in the United States, at least 2 million people
become infected with bacteria that are resistant to antibi-
otics. At least 23,000 people die annually as a direct result
of these infections, while many more die from other con-
ditions that were complicated by an antibiotic-resistant
infection (Frieden 2013). Since the 1980s in the US, newly
approved antibiotics have steadily declined and despite the
increased awareness and redoubled efforts, the current
R&D pipeline remains largely dry (Hughes 2011). The
underlying economic factors make antibiotic development
unprofitable, (Nathan and Goldberg 2005), since it is not
commercially viable to develop new drugs if there is a high
probability of their becoming ineffective soon after intro-
duction (Liljeqvist et al. 2012). One of the major draw-
backs is the inability to discover completely new
antibiotics; those discovered over the last few decades have
now been modified to produce new generic forms (Jose
2010), which is a disincentive to spending money on R&D.
Antibiotics were used in poultry industries to reduce
Salmonella levels at each step of the production in the
farms. Yet Salmonella remains the major cause of food-
borne diseases worldwide, with chickens known to be the
main reservoir for this zoonotic pathogen (FSA 2011;
Bardina et al. 2012). It is the second leading cause of
bacterial foodborne illness in the US and the great majority
of these infections are associated with the consumption of
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products such as poultry and eggs contaminated with Sal-
monella (Foley et al. 2008). Salmonella have evolved
several virulence and antimicrobial resistance mechanisms
that allow for continued challenges to our public health
infrastructure (Foley and Lynne 2008).
The emergence of infectious disease caused by drug-
resistant bacteria requires alternatives to conventional
antibiotics (Barrow and Soothill 1997; Alisky et al. 1998;
Carlton 1999; Sulakvelidze et al. 2001). The search for new
drugs is becoming critical because of the growing concern
over the failing antibiotic drug discovery pipeline. There is
a great deal of interest to investigate alternatives and nat-
ural antimicrobial agents, which has also increased due to
consumer awareness about the use of chemical preserva-
tives in foodstuff and on food processing surfaces.
Bacteriophages
Bacteriophages (phages) are described as viruses that infect
bacteria. Application of phages has been investigated
extensively, such as in the indicator of fecal contamination
(Endley et al. 2003) and against antibiotic resistant bacteria
(Yosef et al. 2014).
Lytic phage
When a virulent phage infects a host bacterium, it repli-
cates much faster than the host cell. The whole cycle can be
completed in 30–40 min. The phage is a parasite that
depends on the host for its propagation, which is influenced
by a variety of factors such as temperature, nutrients, light
and other environmental forces (Jassim and Limoges
2013). It subverts the host’s biological function and utilizes
the host machinery for reproduction. The host cell under-
goes lysis and dies, simultaneously liberating a large
number of progeny phages, which are each then ready to
start another cycle by infecting new neighbouring bacterial
cells. This cycle is known a lytic ‘virulent’ cycle.
The lytic cycle or ‘virulent phages’ fit in the class of
‘natural antimicrobial controlling agents’ and are arguably
the most abundant biological entities on the planet. These
are being exploited in various areas of biotechnology,
including rapid bacterial detection (Stewart et al. 1993;
McIntyre et al. 1996; Stewart et al. 1998; Favrin et al.
2001, 2003; Jassim and Griffiths 2007; Rees and Loessner
2009; Jassim et al. 2011), food bioprocessing (Jassim et al.
2012) and removal of bacterial biofilm (Hibma et al. 1997;
Jassim et al. 2012).
Phages are known to have some advantages associated
with human therapy over the use of antibiotics (Sula-
kvelidze et al. 2001; Sulakvelidze and Kutter 2005; Loc-
Carrillo and Abedon 2011). The inexorable rise in the
incidence of antibiotic resistance in bacterial pathogens,
coupled with the disappointingly low rate of emergence of
new, clinically useful antibiotics, has refocused attention
on the potential utility of phages for biocontrol and pre-
venting or treating human and animal disease.
Lysogenic phage
Other particles, called lysogenic phages, are ‘temperate’ or
dormant phages which may take the form of a ‘prophage’
by integrating with the viral DNA in the host chromosome.
They become a part of the host cell and replicate along
with the host chromosome for many generations, coexis-
ting as opposed to lysing the host cell (Jassim and Limoges
2013). This phenomenon is called ‘lysogeny’, which also
provides immunity against infection by further phage par-
ticles of the same type, ensuring that there is only one copy
of phage per bacterial cell. The unique characteristics of
lysogenic or ‘temperate’ phages and their potential for
exploitation have been demonstrated in a system that
restores antibiotic efficiency by reversing pathogen resis-
tance to antibiotics (Edgar et al. 2012). These phages are
genetically engineered to reverse the pathogens’ drug
resistance, thereby restoring their sensitivity to antibiotics.
Unlike conventional phage therapy, the system does not
rely on the phage’s ability to kill pathogens in the infected
host, but instead, on its ability to deliver genetic constructs
into the bacteria and thus render them sensitive to antibi-
otics prior to host infection. The transfer of the sensitizing
cassette by the constructed phage will significantly enrich
antibiotic-treatable pathogens on hospital surfaces. This
may hold key advantages to revive the use of old genera-
tion antibiotics leading to the use of phage biotechnology
synergistically with antibiotics.
The lysogenic phage or ‘prophage’ will drive the
adaptive evolution of bacteria to achieve more powerful
virulence factors inherited from previously infected bac-
teria via transduction, i.e., the transfer of genetic material
to a bacterial cell via phage infection (Campbell 1988;
Verheust et al. 2010). Lysogenic phages serve as a driving
force in bacterial pathogenesis, acting not only in the
evolution of bacterial pathogens through gene transfer, but
also contributing directly to bacterial pathogenesis at the
time of infection (Wagner and Waldor 2002; Verheust
et al. 2010). The data of Vojtek et al. (2008) has indicated
that horizontal transfer of lysogenic phages among group A
Streptococcus can occur across the M-type barrier; these
data also provide further support for the hypothesis that
toxigenic conversion can occur via lysogeny between
species. This mechanism specifically allows more efficient
adaptation to changing host challenges, potentially leading
to fitter and more virulent clones (Vojtek et al. 2008). Other
authors concluded that this may represent a potentially
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serious hazard to humans, animals and plants (Saunders
et al. 2001; Verheust et al. 2010).
In viruses, recombinational repair is most often studied
as it is manifested in the phenomenon of phage MR,
whereas MR is the process by which viral genomes con-
taining inactivating genomic damage, interact within the
infected cell to form a viable genome (Michod et al. 2008).
MR was found in many phages that infect E. coli (T1, T2,
T5, T6, and phiX174) and Salmonella typhi (Viphage)
(Blanco and Devoret 1973; Michod et al. 2008). The
genome damage expressed as a lysogenic prophage is an
error prone in nature and can be reactivated (Bhattacharyya
et al. 1991; Michod et al. 2008). The restoration of
impaired biologic activity can be caused by chemical
reaction, thermal application, genetic recombination, or
helper elements (Duenas and Borrebaeck 1995; Jassim
et al. 1995; Maloy and Youderian 1996; Rieder et al. 1996;
Maloy and Gardner 1998; O’Sullivan et al. 1998; Gupt
2008; Michod et al. 2008; Jassim et al. 2010).
It is noteworthy that lateral gene transfer virulence
factors can also be accomplished through the lysogenic
phages, which harbour a multitude of prophages and each
phage-encoded virulence or fitness factor makes an incre-
mental contribution to the fitness of the lysogen (Bru¨ssow
et al. 2004; Verheust et al. 2010). This will lead eventually
to the evolution of pathogenic bacteria (Verheust et al.
2010). However, the phage could become a clinically
useful therapy tool through understanding how to control
the phage-resistant bacteria (Mizoguchi et al. 2003; Fischer
et al. 2004). Subsequent studies revealed that not all phages
replicate similarly and that there are important differences
in the replication cycles of lytic and lysogenic phages
(Sulakvelidze et al. 2001; Jassim et al. 2010).
The emergence of phage-resistant mutants is undesirable
and the study of Mizoguchi et al. (2003) employs a con-
tinuous culture to investigate sequential mutations of both
phage PP01 and its host cells E. coli O157:H7. The phage
PP01, previously shown to efficiently and specifically lyse
E. coli O157:H7, showed that co-evolution occurred to the
phage PP01 reducing the phage lytic activity, therefore
they decided to extend their research to find other
O157:H7-specific phages. They also concluded that only
through understanding and controlling the emergence of
phage-resistant bacteria could phage become a clinically
useful tool. It seems that broad-range phage O157:H7-
PP01 resistance by clonal heterogeneity represents a new
class of bacteria–phage interactions (Fischer et al. 2004).
Furthermore, S. enteritidis strains did not produce viable
phages when grown on particular hosts, which behaved as
complexes of phages (Sillankorva et al. 2010). The latter
authors have concluded this is most likely because of the
presence of inactive phage-related genomes (or their parts)
in the bacterial strains which are capable of being
reactivated or which can recombine with lytic phages. In
fact, some of the failures of phage therapy were due to
bacterial mutations leading to resistance to phage infection
(Barrow and Soothill 1997; Alisky et al. 1998; Carlton
1999; Sulakvelidze et al. 2001).
Phage in therapy/bio-control (prophylaxis) applications
There are numerous reviews describing both the potential
for and caveats associated with the employment of phages
to treat bacterial infections, especially in clinical settings
(Goodridge and Abedon 2003). Phage therapy is like other
methods of biological control with some comfort in the
reduction of the use of chemical agents against pathogens
(Fujiwara et al. 2011). The advantages associated with
phage therapy relative particularly to chemical anti-bacte-
rial agents were also reviewed. (Sulakvelidze and Kutter
2005; Loc-Carrillo and Abedon 2011). Phages can be
bactericidal, they can increase in number responding to the
incidence of pathogens over the course of treatment, tend
to only minimally disrupt normal flora, are equally effec-
tive against antibiotic-resistant bacteria, are often easily
discovered, seem to be capable of disrupting bacterial
biofilms, and can have low inherent toxicities. The
exploitation of phages as a realistic approach in the control
of pathogens has attracted considerable interest in recent
years (Sulakvelidze et al. 2001; Merril et al. 2003; Jassim
et al. 2012), because of the emergence of antibiotic-resis-
tant bacteria.
Phage therapeutic applications in various aspects of
human therapy and nonclinical settings are reported (Su-
lakvelidze and Kutter 2005; Bru¨ssow 2007; Go´rski et al.
2007, 2009; Harper and Kutter 2009; Kutter 2009; Kutter
et al. 2010; Abedon et al. 2011; Loc-Carrillo and Abedon
2011). Phage treatment in human eyes, ears and nose via
inhalation was used at the Eliava Institute in Tbilisi for
decades (Kutter et al. 2010; Abedon et al. 2011). Recently,
phages have been suggested to be included in a nebulizer to
treat bacterial lung infections in cystic fibrosis patients
(Golshahi et al. 2008) or to be sprayed as dried phages in
respirable powders for the treatment of pulmonary infec-
tions (Matinkhoo et al. 2011). The first controlled clinical
trial of a therapeutic phage preparation was conducted
in 2009 and showed efficacy and safety in chronic otitis
targeting antibiotic-resistant Pseudomonas aeruginosa
(Wright et al. 2009). A year later, in an evaluation of a
phage treatment for chronic otitis infection in dogs, the
results show once more that administration of this topical
phage mixture leads to lysis of P. aeruginosa in the ear
without apparent toxicity and that it has potential to be a
convenient and effective treatment for P. aeruginosa otitis
(Hawkins et al. 2010).
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In the area of animal biocontrol and agribusiness
options, phages have shown a remarkable success (Smith
et al. 1987; Biswas et al. 2002; Sulakvelidze and Barrow
2005; Hawkins et al. 2010). Phages have been extremely
effective at treating a number of bacterial infections in
controlled animal studies, especially as a biocontrol agent
in the prevention of food-borne illnesses, due to its target
specificity, rapid bacterial killing and ability to self-repli-
cate (Smith et al. 1987; Biswas et al. 2002; Hawkins et al.
2010). Phages have the potential to treat bacterial infec-
tions afflicting animals and in particular to prevent fatal
Escherichia coli respiratory infections in broiler chickens
(Huff et al. 2002a, b, 2003a, b). Aerosol spraying and
intramuscular injection have given the best results over
using oral delivery of phages via direct administration or
addition to drinking water and/or feed (Sillankorva et al.
2012). This is may be due to gastric pH levels preventing
the proliferation of phages (Spits 2009). Virulent antigen-
specific phages have been used in an attempt to control
E. coli O157:H7 in batch culture (Kudva et al. 1999). Loc-
Carrillo et al. (2005) and Wagenaar et al. (2005) reported
that phage therapy (biocontrol) reduces Campylobacter
jejuni colonization of broiler chickens. Several studies have
also addressed the use of phages to decrease Campylo-
bacter and Salmonella concentrations on poultry (Goode
et al. 2003; Atterbury et al. 2007; Kittler et al. 2013).
Veterinary therapy/biocontrol applications require the
appropriate administration targeting specific bacteria, with
a strategy that includes a comprehensive methodology,
detailing the phage-host interactions, dose optimization and
accounting for all chemical and physical factors (Jassim
and Limoges 2013). In general, a deep understanding of
intrinsic phage properties is critical to designing thera-
peutic interventions. The reduction of foodborne pathogens
requires a comprehensive phage control program at the
farm, where the animals are born, hatched or raised, before
shipment to processing plants. Potential pre-harvest sour-
ces of foodborne pathogen contamination include breeder
herds and flocks, hatcheries, contaminated feed and water,
along with environmental sources and vectors, such as
litter, animal caretakers, and insects (Bailey 1993; Nayak
et al. 2003).
Regulatory approval of phage therapy
Classical phage treatments used since the 1920s in the
Soviet era is being investigated as another potential strat-
egy (Potera 2013). Since phages are part of both gastro-
intestinal and environmental ecosystems (Topley and
Wilson 1990), bactericidal phages may provide a feasible
natural, nontoxic approach for controlling several human
pathogens (Alisky et al. 1998). The safety of phages was
further assured by Duckworth and Gulig (2002) who stated
that there has been no evidence that exposure to phage
particles, even those normally associated with disease-
causing bacteria, can actually result in the occurrence of
human disease. Nevertheless, Borysowski and Go´rski
(2008) examined the safety of phage therapy, especially in
immunocompromised individuals. They discussed the
possible negative interactions with the immune system and
the relative safety of the therapy compared to its effec-
tiveness since phage resistant bacteria and some phage
preparations, especially lysates, have been found to exert
immunostimulatory activity. This problem is of great
importance in phage therapy since immune response-
mediated antibacterial activity may be substantially sup-
pressed in immunocompromised patients. In addition,
another safety aspect might be taken into consideration,
phages replicate at the site of infection or wherever the host
bacteria are present, while phages are absent in sterile
areas, thus ensuring an optimal self-adjusting dose of
phages which is not found in other modes of non-biological
antimicrobial agents (Katsunori 2003). These arguments
have helped to pave the way for phage therapy/biocontrol
to become a broadly relevant technology, including veter-
inary, agricultural, and food microbiology applications.
It was for the treatment or prevention of human infec-
tions that phage therapy first caught the world’s imagina-
tion and which today is the primary motivation of the field
(Zhukov-Verezhnikov et al. 1978; Biswas et al. 2002;
Merril et al. 2006; Hawkins et al. 2010; Kittler et al. 2013).
Nevertheless, the regulatory requirements for these types of
live drugs, phages are still challenging (Potera 2013) and
their uses might not extend to life-threatening infections.
The recent USFDA (2006) approval of Listeria-specific
phage preparations for food additives has opened the door
to new applications of these natural bacterial killers. It is
known that phages only infect and lyse bacterial cells and
are harmless to mammalians (USFDA 2006). This has
eventually led to the development of a phage related
product which received regulatory approval from the FDA
in 2011, as a natural antimicrobial for use in agro-food
industry as GRAS and by US-FSIS as safe for use in ani-
mals (Sillankorva et al. 2012; Klumpp and Loessner 2013).
In general, although the safety of phages has been strongly
suggested by human phage therapy, it should be noted that
some phages, notably when in the form of lysogens (pro-
phages), have been recognized as important contributors to
bacterial virulence, or as vectors in horizontal gene transfer
through transduction (Verheust et al. 2010) as discussed
further below.
Current information regarding studies being conducted
and/or ongoing trials with the primary purpose of experi-
mental therapy to treat, with the aid of phages, patients
with various infections can be obtained from www.
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clinicaltrial.gov; http://www.clinicaltrial.gov/ct2/result
s?term=phage?therapy&Search=Search; Parracho et al.
(2012). The national and international regulatory compli-
ance and regulations being employed can be obtained from
Parracho et al. (2012).
Phage experimental evolution
Replication inside host bacteria by a lytic phage is a
complex process consisting of a cascade of events
involving several structural and regulatory genes (Sula-
kvelidze et al. 2001). Some therapeutic phages have unique
yet unidentified genes or mechanisms responsible for their
ability to effectively lyse their target bacteria. For example,
a group of authors from the EIBMV (Adamia et al. 1990)
identified and cloned an anti-Salmonella phage gene
responsible, at least in part, for the phage’s potent lethal
activity against the S. enterica serovar typhimurium host
strains. In another study (Andriashvili et al. 1986), a unique
mechanism has been described for protecting phage DNA
from the restriction-modification defences of Staphylo-
coccus aureus host strain.
Phage gene expression has been studied by many
researchers (Gupt 2008). Use of genetic virus design/
breeding which is a genetic manipulation of the virus
genome has been reported (Duenas and Borrebaeck 1995;
Rieder et al. 1996; Barrow and Soothill 1997; Alisky et al.
1998; O’Sullivan et al. 1998). Expression of the ant gene,
to determine the lysis-lysogeny decision of phages was also
reported (Maloy and Youderian 1996; Maloy and Gardner
1998). This provides a positive selection for and against
DNA-binding: repression of ant can be selected by
requiring growth of lysogens, and mutants that cannot
repress ant can be selected by requiring lytic growth of the
phage. The use of genetically engineered nonlytic phage to
specifically target and deliver DNA encoding bactericidal
proteins to bacteria was reported (Hagens and Bla¨si 2003;
Westwater et al. 2003). The genetically engineered phage
exerted a high killing efficiency while leaving the cells
structurally intact. The use of recombinant viral particles in
some instances might raise some biosafety concerns by
bringing and potentially disseminating new genetic traits
among bacterial populations (Verheust et al. 2010).
The identification of bacteriolytic peptides derived from
phage could rekindle interest in phage as a source of a new
generation of agents for combating multidrug resistant
bacteria and offer a starting point for new therapeutic
agents that could potentially circumvent such problems
(Bernhardt et al. 2001a, b). It was reported that phages
produce lysins which break bonds in the bacterial cell-wall
peptidoglycan structure just before release of phage prog-
eny and that the lysins enzymes have killed bacteria
in vitro within 5 s (Nelson et al. 2001; Schuch et al. 2002).
Further work with lysins enzymes may produce an effec-
tive bactericide and enhanced rapid diagnostic tools.
The efficiency of the in vivo ‘therapy’ use of lytic
phages relies mainly on how robust, rapid and what specific
action phages are able to exert before the immune system
of the body being treated will reduce them below the level
of effectiveness (Abedon et al. 2011). Therefore, it seems
that the less robust, un-optimized, phages have less chance
to succeed in abolishing in vivo bacterial infection than
their robust, optimized counterparts. Moreover, it seems
that the in vitro challenge of the attacking phages against
host bacteria might be limited by the availability of highly
efficient and specific phages for challenging each pathogen
successfully.
Modern phage technology: obstacles and indications
Although phage therapy has been practiced for several
decades in some of the former Soviet Union countries and
Poland, there are still many doubts as to its ability to
replace antibiotics (Edgar et al. 2012). They are not yet
‘‘magic bullets’’ and they might not work in certain settings
(Sulakvelidze 2011). The development of obligate lytic
phages may provide one modality to kill only specific
pathogens without harming beneficial flora. There are other
issues to address, including the potential in vivo elimina-
tion of phages, phage-neutralizing antibodies and phage-
resistant mutants (Sulakvelidze 2011).
Human infections caused by pathogens transmitted from
fish or the aquatic environments are quite common and
depend on the season, as well as patients’ contact with fish
and the related environment (Novotny et al. 2004). It is
well known that fish and seafood are a potential source of
many foodborne pathogens for human beings (Novotny
et al. 2004). The effects of phage-host interactions in a
commercially important fish pathogen were studied (La-
anto et al. 2012). They reported that Flavobacterium col-
umnare has developed resistance to 3 lytic phages
associated with a decline in the bacterial virulence. They
have hypothesised that this is due to antagonistic co-evo-
lution factors reducing the virulence of bacterial pathogens
outside of a host due to the associated costs of defending
against lytic phages. This study represents the first report
that phage-based therapies can provide a disease manage-
ment strategy for columnaris disease in aquaculture (La-
anto et al. 2012).
The recently discovered, Sputnik virophage is a satellite
virus that inhibits replication of its target phage and thus
acts as a parasite of that virus in aquatic environments
(Jassim and Limoges 2013). These virophages may also
coexist as the natural predator of the phages that target
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foodborne pathogens, perhaps transmitted from their
aquatic environments by fish and seafood. Virophages in
aquatic environments hijack virus DNA in order to repli-
cate and often deform phage/virus particles, making them
less infective (Jassim and Limoges 2013). We have found
no published report of their existence or survival outside of
aquatic environments, but if confirmed, it may help to
explain why, according to the US Center for Science in the
Public Interest (CSPI 2008), fish and shellfish are more
likely to cause foodborne-illness than any other category of
food product. Even if these virophages exist only in aquatic
environments, much of their work to hamper the effec-
tiveness of phages is already accomplished prior to the
food harvest. These foods are also considered a potential
entry source of foodborne pathogens into the home (Scott
2003). It is worthwhile to investigate this postulation and
potential association of virophages with aquatic foodborne
pathogens in order to aid the understanding of phage
ecology and bacterial evolution in greater clarity, assisting
in the application of phages in therapy and biocontrol of
bacterial infections.
The development of phage resistance by bacteria is an
issue facing scientists investigating phage-bacteria inter-
action. Phage-mediated transduction of bacterial genes
likely reflects an infrequent mistake in the assembly of the
phage particle, rather than a bacterial adaptation (Michod
et al. 2008). The mechanism that caused the spread of
antibiotic resistance genes between bacteria occurs most
often by the gene transfer process of plasmid mediated
conjugation and sometimes by phage-mediated transduc-
tion (Michod et al. 2008).
Phage interactions and/or to allow irreversible phage
binding to the E. coli O157 antigen was studied (Kudva
et al. 1999). It was found that the movement of virions in
the LPS layer before DNA injection may involve the
release and rebinding of individual tail spikes rather than
hydrolysis of the O-antigen (Baxa et al. 1996). This would
suggest that effective infection might require normal LPS,
thus, phage mutations seem to originate by alternation of
LPS structure (Mizoguchi et al. 2003). The importance of
LPS of the outer membrane in controlling the fate of phage
attachment and the consequent phage infection of the host
cell was reported (Mizoguchi et al. 2003). It was inferred
that the modification of LPS of the outer membrane of host
bacteria may play a key role in controlling the phage-host
interaction and consequently control phage infection.
In general, phage host interactions are dependent on the
binding of tail proteins to specific bacterial surface recep-
tors (Pelczar et al. 1993). It seems that the development of
a successful phage against target bacteria must address the
emergence of mutant strains, the phage binding and
infection of bacterium not being controlled by a single
receptor, and the many factors which contribute to phage
resistance including alteration or loss of receptors for the
target cell envelope (Heller 1992; Barrow et al. 1998; Bi-
swas et al. 2002; Mizoguchi et al. 2003; Jassim et al. 2010).
Thus, the efficient use of phages to control bacterial
infections may require isolation of mutant host-specific
phages that can adsorb to hosts that make shorter O-side
chains (Kudva et al. 1999). Practical application might be
hampered by factors such as the lack of broad-host phages
and heterogeneity (Kutter 2005). The ecology of both
phages and bacteria were also not understood, resistance,
failure to neutralize gastric pH prior to oral administration,
inactivation of phages by host immune responses and
environmental contamination issues are other obstacles
(Kutter 2005). It was also suggested that changes of the
bacterial hosts used for maintenance of phages must be
avoided as these can drastically modify the parameters of
the phage preparations, including host range and lytic
activity (Sillankorva et al. 2010; Sulakvelidze 2011). The
generally poor efficacy of commercial phage preparations
led to widespread criticism and disagreement about the
effectiveness of phages in treating disease (Atterbury
2009).
Another drawback is the survival and persistence of
phages on different surfaces due to the impact of external
forces on phage-host interactions in their surrounding
environments (Jassim and Limoges 2013). Phage virility is
affected by physical and chemical factors associated with
the microscopic food matrix and with the conditions of
application including environmental factors and the distinct
properties of the phage itself (EFSA 2009). All these
aspects must be investigated and well characterized before
an effective biocontrol agent can be established and mar-
keted (Bardina et al. 2012). The success of phage biocon-
trol to greatly reduce harmful bacteria entering the food
chain at farm level requires the production of virulent
phages that can survive in extreme environments and
having a broad host range for the target genus, while
lacking bacterial virulence genes.
Phage safety and efficacy for therapy
Phage bactericidal activity
Phage biocontrol is applying specific phages to selectively
reduce or eliminate susceptible bacteria from selected
environments, including human and animal bodies, artifi-
cial environments, such as farms, factories, offices, hospi-
tals, or in laboratory (Kurtbo¨ke et al. 1992; Grandgirard
et al. 2008). The ability of phages to recognize precisely
their target hosts, rendered them as favourable antibacterial
agents because broad-spectrum antibiotics kill target bac-
teria along with other beneficial bacteria present in the
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farm or in the organism body, namely, animal intestinal
flora (Merril et al. 2003).
Bacterial resistance to phages will unquestionably
develop, although according to some authors (Carlton
1999; Inal 2003; Tanji et al. 2005) the rate of developing
resistance to phages is approximately 10-fold lower than
that to antibiotics (Sulakvelidze et al. 2001). Furthermore,
many earlier studies demonstrated that classical application
of phages in bacterial therapy or biocontrol is attainable in
theory but in practice were not so successful, due to the
lack of full coverage of target bacteria and the rapid
emergence of bacterial mutations leading to complete
resistance against phage infection (Barrow and Soothill
1997; Alisky et al. 1998; Carlton 1999; Sulakvelidze et al.
2001; Goodridge and Abedon 2003). Therefore, phage
therapy or phage biocontrol were unsuccessful and even-
tually led to replacement of phage therapy with antibiotic
treatment (Barrow and Soothill 1997). Scientific method-
ologies could be developed to deal with antibiotic resis-
tance in bacteria using bacteriophage, however viral
proteins would also integrate into human and animal
society with unknown effect. Viral based therapy could
potentially lead to bacterial development of viral resis-
tance. It would be wise to approach such methodologies
with caution in order to avoid repeating mistakes that were
made with the improper use of antibiotics. Other authors
have refuted these assumptions and concluded that the rate
of developing resistance against phages can be partially
circumvented by using several phages in one preparation or
cocktail (much like using two or more antibiotics simul-
taneously) (Sulakvelidze et al. 2001). More importantly,
unlike using trial and error with antibiotics, when resis-
tance against a given phage occurs, the specialists can
rapidly select through testing (in a few days or weeks) a
new phage that is effective against the phage-resistant
bacteria (Sulakvelidze et al. 2001).
Therapeutic phages have some other advantages over
antibiotics (Sulakvelidze et al. 2001; Sulakvelidze and
Kutter 2005; Loc-Carrillo and Abedon 2011), and phages
have been reported to be more effective than antibiotics in
experimentally infected animals (Smith and Huggins
1982). Like bacteria but unlike antibiotics, phages mutate
and therefore can also evolve to counter phage-resistant
bacteria (Matsuzaki et al. 2005). Because phages attack
bacteria by attaching to receptors on the bacterial cell
surface, phage-resistant mutants (which lack these recep-
tors) are often less pathogenic than phage-susceptible
bacteria (Inal 2003; Santander and Robeson 2007; Cap-
parelli et al. 2010; Friman et al. 2011; Laanto et al. 2012).
Despite the attractions of phage therapy, scientific and
logistical challenges remain. Wild-type phage particles are
rapidly eliminated by the body’s reticuloendothelial
(mononuclear phagocyte) system, so in order to enhance
phages’ circulatory time and improve the efficacy of
treatment; long-circulating mutants (Merril et al. 1996;
Keen 2012) must be selected. Wild-type virion and distri-
bution concerns relating to the scalability of phage therapy
have also been discussed (Lu and Koeris 2011). More
broadly, for phage therapy to be useful in clinical settings,
a patient’s specific etiological agent would need to be
rapidly identified and matched to the relevant phage(s) in a
comprehensive pre-existing database. Because this sce-
nario is inconsistent with how antibiotics are traditionally
employed (Bull et al. 2002), new and interdisciplinary
thinking involving bioinformaticists, health care profes-
sionals, and phage researchers, among others, would be
required to make phage therapy practicable on a large
scale.
For oral therapies to be optimized, the phages must be
shielded with a non-immunogenic polymer such as poly-
ethylene glycol (Kim et al. 2008). On the other hand, the
pharmacokinetics of self-replicating agents such as phages,
differ from those of normal drugs (Robert et al. 2000;
Bru¨ssow 2005) which needs further investigation. Study of
phage-bacterial-host cell interactions such as those carried-
out by Cairns et al. (2009) to improve understanding of
phages in vivo pharmacokinetics, including relevant inun-
dation, proliferation thresholds, optimisation of formula-
tions and long-term stability data is required before it can
be widely used within a clinical setting (Abedon et al.
2011; Ryan et al. 2011; Parracho et al. 2012).
It is also unclear how effective phages would be in
treating diseases caused by intracellular pathogens (e.g.,
Salmonella species), where bacteria multiply primarily
inside body cells where they are inaccessible to phages. It
is possible that phages will have only limited utility in
treating infections caused by intracellular salmonella in
children (Kiknadze et al. 1986). It was found that the most
successful route of administration for the treatment of
systemic infections was via the parenteral route. Oral
delivery is mainly used to treat gastrointestinal infections.
However, in some cases phages can also reach the systemic
circulation. Local delivery (skin, ears, and teeth) has
proved extremely successful in the treatment of topical
infections, as has the inhalation of phages for the treatment
of lung infections (Ryan et al. 2011).
In order to ultimately incorporate phage therapy into a
larger antibacterial arsenal, a regulatory framework must
exist that allows phages to be utilized to their maximum
potential. Classical phage therapy is a form of personalized
medicine because specific phages (usually multiple phages
combined as a multivalent cocktail) are carefully selected
to treat a patient’s specific bacterial infection. Success rates
from these customized phages are five-to-six fold higher
than that of standardized phage products (Zhukov-Vere-
zhnikov et al. 1978), so the use of personalized phage
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cocktails has historically been crucial for effective treat-
ment. This is most likely because of the presence of
inactive phage-related genomes in the host strains which
are capable of being reactivated or which can recombine
with lytic phages (Sillankorva et al. 2010).
Phage pharmacological study
Despite the large number of publications on phage therapy,
there are very few reports in which the pharmacokinetics of
therapeutic phage preparations is delineated (Payne et al.
2000; Robert et al. 2000; Payne and Jansen 2003; Levin
and Bull 2004; Bru¨ssow 2005; Go´rski et al. 2006; Gill
2008; Cairns et al. 2009; Abedon and Thomas-Abedon
2010; Gill 2010; Abedon et al. 2011; Parracho et al. 2012).
The studies of Bogovazova et al. (1991) and Bogovazova
et al. (1992) suggested that phages get into the bloodstream
of laboratory animals (after a single oral dose) within 2–4 h
and that they are found in the internal organs (liver, spleen,
kidney, etc.) in approximately 10 h. Also, data concerning
the persistence of administered phages indicate that phages
can remain in the body for relatively prolonged periods of
time, i.e., up to several days (Babalova et al. 1968). In one
study, the time needed for the phage to reduce, eliminate or
cure the target bacteria in infected animals was defined as a
reduction of Salmonella concentration in the chicken
cecum, and obtained when the phage was administered one
day before or just after bacterial infection and then again
on different days post-infection (Bardina et al. 2012). In
comparison, calves and piglets with diarrhea due to
experimentally administered pathogenic E. coli were cured
within 8 h following phage administration (Smith and
Huggins 1983). Hence, elimination of the pathogenic
E. coli at the pre-harvest stage could play a significant role
in preventing its introduction into the food chain (Tauxe
1997). These results would suggest that due to the phage
short-term effect; the application would be optimized
according to the type of chronic infection with the length of
time before slaughter that is required to control the par-
ticular infection for the animals.
Another noteworthy issue regarding pharmacokinetic
study is that phage-neutralizing antibodies were reported
(Geller et al. 1998). This could be one of the principal
reasons phages had failed as a therapeutic, through their
supposed inactivation by pre-existing antibodies (Carlton
1999). Phage immune response was also observed in a
mice study (Sabah A A Jassim unpublished data). Rats or
humans can develop effective immunity against all intro-
duced phages (Merril et al. 2006). It seems the pharma-
cokinetic aspects of phage therapy pharmacology need
considerable research in order to obtain rigorous pharma-
cological data concerning both lytic and lysogenic phages,
including full-scale toxicological studies, before lytic
phages can be used therapeutically in humans. Overall,
Kutter et al. (2010) has concluded that to provide an
overview of the potential of phage therapy as a means of
treating or preventing human diseases, there is a need to
explore the phage therapy state of the art as currently
practiced by physicians in various pockets of phage therapy
activity around the world.
Future directions
Phage development and producing preparations as anti-
dotes or as a biocontrol from farm to fork, requires an
understanding of the obstacles associated with the use of
‘live drugs’ or phages.
Challenges
There is renewed optimism for phages as possible new
‘live drugs’ with hope to overcome the multi drug resistant
bacteria problem. Surprisingly, despite the approval to use
phages in food and medical industries by several interna-
tional agencies FDA, GRAS, US-FSIS (see Regulatory
approval of phage therapy), phages have not gained
widespread acceptance as compared to commercially pro-
ven pharmaceutical antimicrobial agents.
The following summary outlines the key issues in phage
biocontrol and treatment that scientists have already
encountered both in the literature as well as in the labo-
ratories. These can help to frame a platform from which
past mistakes with both phages and antibiotics can be
avoided.
Summary of key obstacles to best practices with phage
in modern applications
• Heterogeneity and ecology of both phages and bacteria
were not understood.
• Need to select highly virulent phages against target
bacteria in the patient.
• Single phage preparations used to treat mixtures of
different bacteria.
• Recognition as personalized medicine using a multi-
valent cocktail carefully selected to treat a patient’s
specific bacterial infection(s).
• Lack of standardized lytic phages that can target only
their host cell without using genetic modification.
• Genetically modified phages changing the composition
of colonizing bacterial flora in humans, risk of
subsequent development of active infections.
• Lateral gene transfer virulence factors and antibiotic
resistance.
• Restriction modification degradation of phage DNA
upon infection.
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• Resistance mutations in bacterial genes for adsorption,
lysogeny and lysogenic conversion. Strict safety stan-
dards for human therapies not met.
• Toxigenic conversion via lysogeny between species
allowing more efficient adaptation of host, potentially
leading to fitter and more virulent clones.
• Failure to appropriately characterize or titre phage
preparations.
• Changes in the bacterial cell envelope for example, use
of antibiotics in animal production that can cause
disruption of microbial cell wall synthesis.
• Effect of environmental factors which all contribute to
the complexity and unpredictability of phage-host
interactions in the field such as UV light, chemical
disinfectants, nutrients, pollutants etc.
• The isolation and the cultivation of phages from natural
sources are time consuming and problematic for
producing large amounts of active inoculums.
• Failure to characterize phage preparation, i.e., to
determine the virulence to the target.
• Failure to neutralize gastric pH prior to oral
administration.
• Immunogenicity antibodies developed against phage.
• Presence of endotoxins in phage preparation leading to
toxic shock in the patient.
• Pharmacokinetics of self-replicating agents differs from
those of normal drugs.
• In vivo susceptibility of bacterial pathogens to phages
is poorly understood and future research on more
phage-host cell interaction needed to define the
requirements for successful phage treatments.
• Many phage experiments done in vitro models need to
be extrapolated to in vivo growth.
• Phages can be reproduced from a commercially available
phage preparation, a challenge to commercialization.
• Intellectual property rights are challenging for the use
of phage therapy in modern medicine and these can also
trigger ethical discussions.
• In the healthcare system phage therapy is still seen as a
cost and a social program rather than an economic
driver.
• Phage sectors need more time to develop entrepreneurs
and innovation in their sector.
Phage reprogramming
Although most phages do not represent a threat to human
health (unless they are carrying virulence factors), the use
of recombinant viral particles in some instances might raise
some biosafety concerns by bringing and potentially dis-
seminating new genetic traits among bacterial populations
(Verheust et al. 2010). Jassim et al. (1995) and Jassim
et al. (2010) have described novel non-genetically mod-
ified phage breeding and design technologies, respec-
tively, for previously resistant bacterial strains. It is of
particular importance to determine the host range of the
phages that will be used within the complicated animal
environments, for example the use of antibiotics in animal
production can generate cell wall deficient or cell wall
disrupted bacteria. The bacterial cell wall is the most
important part of the bacterial structure for the phage
attachment, required to initiate bacterial infection. Phage
technology was previously developed for cell wall defi-
cient bacteria using non-genetically bred phages by a
Jassim research team (Hibma et al. 1997). On the other
hand, some phages can infect a number of bacteria strains,
while others are more specific and will only infect a
particular sub-strain. The evolutionary survival of viruses
is attributed to five realities (Jassim et al. 1995; Jassim
and Naji 2003; Jassim 2005; Jassim et al. 2010; Jassim
and Limoges 2013):
• Genetic variability,
• Variety in means of transmission,
• Efficient replication within host cells,
• Ability to remain dormant within the host (lysogeny),
• Environmental or external forces.
Based on the above concepts, phage selectivity cultures
(Jassim et al. 1995) and phage design technology (Jassim
et al. 2010) were developed to address phage-host inter-
actions and to produce highly lytic phages with no or far
less phage-resistant mutants, along with broad host tar-
geting capabilities. These methods do not employ genetic
modification, to breed ‘‘re-tailored’’ wild phages on the
host cells in order to gain newly bred sub-strains of phages
which are able to overcome the host defence mechanisms
in order to infect previously resistant bacteria and to play
an important role in future applications (Jassim et al. 1995;
Hibma et al. 1997). Newer methodologies are used to
reprogram phages again without genetic modification, to
possess auxiliary mechanisms for phage adherence/binding
and uptake that are critical for plaque formation, in order to
gain new sub-strains of phages able to infect parent resis-
tant host cells. This non-genetic approach of the technology
is environmentally-driven and so mimics natural selection
or evolution of the phage by reproducing vast numbers of
mixed populations of the most robust wild-type phages.
Phage reprogramming technology was developed (Fig. 1)
to permit a better selection and adaptation of robust lytic
phages for each potential application. This technology is
capable of converting naturally occurring wild phages to
smart phages with a broader range of host specificity that
can overcome a bacterium’s resistive defense mechanisms
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and completely destroy the target bacterial cell. These
findings encourage new optimism and a re-evaluation of
the potential for phage therapy.
Discussion
Phages are naturally occurring predators of bacteria. They
can be effective antibacterial agents due to their specificity
against a particular bacterial species and lack of impact on
other microflora. However, the potential problem still
exists, that just as bacteria are able to become resistant to
antibiotics, they may also be able to develop resistance to
phages. Thus during the course of phage treatment, the
etiologic agents should be continuously monitored for
phage susceptibility and if phage resistance is developed,
the subject phages can be replaced with different phages,
lytic against the newly emerged, phage-resistant bacteria
mutants.
The lysogenic phage contributes by providing axes force
in bacterial pathogenesis and contributing in the bacterial
pathogens evolution through horizontal gene transfer.
Therefore, the development of a successful phage thera-
peutic against medically important human and animal
pathogens must address the emergence of all of these
mutant strains. Specialists must focus on modelling phage
systems in natural ecosystems to prevent bacterial resis-
tance to the phage, which must be addressed before using
phage therapy/biocontrol.
Furthermore, no consensus exists on how quickly pha-
ges should produce results to identify patients who really
need phage therapy. Should the research need to invest in
developing smart phages that can produce results to pre-
vent phage resistance to the host cell? If so, very few
researchers have technologies in their pipelines that can
meet these requirements. Should a first dose of phages be
given and then treatment adjusted on the basis of phage
resistant mutants test results? How do the parameters (e.g.;
speed, robustness of phages, cost, and user friendliness) fit
with the different treatment settings? There is a need to
develop phage technology that is able to provide rapid,
exceptional viruses that produce less phage-resistant bac-
teria mutants in the target pathogens.
Figure 2 illustrates the main strands of a possible strat-
egy based on analysis of the literature and reports pub-
lished in peer reviewed/scholarly journals. The aim is to
develop an action plan for safe phage therapy and business
management to promote the use of phage therapy in
appropriate health care applications.
In parallel there is an equal need for rapid detection
methods, also able to detect swiftly any phage-resistant
mutants so that corrective therapeutic measures can be
taken before putting the patient’s life in danger. The
identification of which organisms caused the infection
using rapid detection methods is paramount, allowing
doctors to know which phages are needed. Knowing which
phage-resistant mutants are always expressed in vivo
would allow these to also be targeted in the system. Many
phage companies are struggling to align their business
goals with the technology solutions because these funda-
mental questions have not been properly addressed by
experts in the specialty. The world needs to rethink phage
technology and realize that human and animal healthcare
with the sharp increase of multi drug resistant bacteria, can
be an economic driver that utilizes innovation fostered in
the life science sector. Antibiotics are currently being
phased out of animal production in many countries.
Researchers are keen to continue to explore the science
behind phage therapy uses, however, it remains unclear if
phage therapy will indeed save lives on a significant scale
or if it will ultimately fail to fulfil its promise. One thing
seems clear though, if phage therapy is to move out of the
twentieth century and into the twenty-first, so too must the
regulatory models that govern it (Keen 2012). Obviously
classical phage therapy did not produce consistently
favourable results leaving antibiotics the preferred treat-
ment. Though many believe that phages will not replace
antibiotics right away or maybe ever, there is definite
Fig. 1 Non-genetic phage
reprogramming technology to
produce smart lytic phage
(Source: Applied Bio Research
Inc.)
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potential for their use in conjunction with antibiotics (Clark
and March 2006).
Conclusion
Phages are presenting solutions that will help to replace,
curb, or promote judicious use of antibiotics in farm ani-
mals. Phage therapeutic approaches are also appropriate as
adjunctive therapies to increase the efficacy of antibiotic
treatment while simultaneously supporting probiotic sup-
plements and useful microflora. As yet phage clinical
therapy is in a progressive and scientific cumulative stage.
To move into the pharmaceutical stage, it needs compe-
tencies, best practices and data that can support pharma-
ceutical industries to develop phage therapy ‘live drugs’.
Innovative phage treatments will benefit from a new under-
standing of the phage-host–pathogen and environmental
interactions. These are long-term solutions to the challenge
of antibiotic resistance, driven by the urgent and growing
need for new treatments.
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